Literature DB >> 7871002

5HT drugs in animal models of anxiety.

S L Handley1, J W McBlane.   

Abstract

It has been widely accepted that 5HT neurones promote anxiety, in humans as well as in animal models. This could be termed the "classic" hypothesis and it has led to a determined search for drugs which reduce 5HT function, especially agents which have selective actions at 5HT receptor subtypes. However, these novel agents tend to have weak and/or variable effects in animal models and more detailed examination of their actions suggests that not all findings are accounted for by the classic hypothesis. There appear to be circumstances in which increased 5HT activity can reduce anxious behaviour. There is increasing evidence for multiple anxiety mechanisms, which may be able to explain differential patterns of drug effects within and between models. Animal models of anxiety may also detect non-anxiety factors: effects on cognition or on impulsivity could be reflected in some models. This could be important in the light of recent evidence that 5HT-selective reuptake inhibitors are effective in impulsivity disorders. The classic hypothesis of 5HT function in anxiety may be only one part of an increasingly complex story. Unravelling the rest of this story is likely to lead to new insights in our understanding of anxiety and related disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7871002     DOI: 10.1007/bf02247358

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  70 in total

1.  Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test.

Authors:  B Söderpalm; S Hjorth; J A Engel
Journal:  Pharmacol Biochem Behav       Date:  1989-01       Impact factor: 3.533

2.  The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behavior in the rat.

Authors:  S S Tenen
Journal:  Psychopharmacologia       Date:  1967

3.  Tryptaminergic mechanisms in punished and nonpunished behavior.

Authors:  F G Graeff; R I Schoenfeld
Journal:  J Pharmacol Exp Ther       Date:  1970-06       Impact factor: 4.030

4.  The involvement of nigral serotonin innervation in the control of punishment-induced behavioral inhibition in rats.

Authors:  M H Thiébot; M Hamon; P Soubrié
Journal:  Pharmacol Biochem Behav       Date:  1983-08       Impact factor: 3.533

5.  Monoaminergic mechanisms in aversive brain stimulation.

Authors:  R S Kiser; R M Lebovitz
Journal:  Physiol Behav       Date:  1975-07

6.  Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.

Authors:  I K Wright; M Heaton; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

Authors:  J A Engel; S Hjorth; K Svensson; A Carlsson; S Liljequist
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

8.  Effects of ritanserin on aversive classical conditioning in humans.

Authors:  R Hensman; F S Guimarães; M Wang; J F Deakin
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

9.  Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat.

Authors:  S Pellow; A L Johnston; S E File
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

10.  Opposite control mediated by central 5-HT1A and non-5-HT1A (5-HT1B or 5-HT1C) receptors on periaqueductal gray aversion.

Authors:  F Jenck; C L Broekkamp; A M Van Delft
Journal:  Eur J Pharmacol       Date:  1989-02-28       Impact factor: 4.432

View more
  23 in total

1.  Measuring anxiety- and locomotion-related behaviours in mice: a new way of using old tests.

Authors:  Leanne M Fraser; Richard E Brown; Ahmed Hussin; Mara Fontana; Ashley Whittaker; Timothy P O'Leary; Lauren Lederle; Andrew Holmes; André Ramos
Journal:  Psychopharmacology (Berl)       Date:  2010-05-08       Impact factor: 4.530

2.  The use of sudden darkness in mice: a behavioural and pharmacological approach.

Authors:  Bettina Bert; Luciano F Felicio; Heidrun Fink; Antonia G Nasello
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  Immediate and long-term effects of 5,7-dihydroxytryptamine on rat striatal serotonergic neurons measured using in vivo voltammetry.

Authors:  T Nakazato; A Akiyama
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

4.  Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo.

Authors:  Nicole R Sullivan; James W Crane; Katerina J Damjanoska; Gonzalo A Carrasco; Deborah N D'Souza; Francisca Garcia; Louis D Van de Kar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-18       Impact factor: 3.000

5.  Cerebral tryptophan hydroxylase activity, and 5-HT1A receptor, 5-HT2A receptor, and 5-HT transporter binding in grouped and isolated Roman RHA and RLA rats: relationships with behaviours in two models of anxiety.

Authors:  A Kulikov; N Castanon; P Mormède; F Chaouloff
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 6.  Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics.

Authors:  K A Miczek; E M Weerts; J A Vivian; H M Barros
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

7.  Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala.

Authors:  Jamie L Scholl; Shawn M Vuong; Gina L Forster
Journal:  Eur J Pharmacol       Date:  2010-07-23       Impact factor: 4.432

8.  The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

Authors:  I Artaiz; G Romero; A Zazpe; A Monge; J M Calderó; J Roca; B Lasheras; J Del Río
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

9.  Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats.

Authors:  M D S Lapiz-Bluhm; C O Bondi; J Doyen; G A Rodriguez; T Bédard-Arana; D A Morilak
Journal:  J Neuroendocrinol       Date:  2008-07-30       Impact factor: 3.627

10.  Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests.

Authors:  Artur H Swiergiel; Adrian J Dunn
Journal:  Pharmacol Biochem Behav       Date:  2007-02-16       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.